Zilucoplan: Molecular Structure

Molecular Structure#

Zilucoplan is a 15-amino acid synthetic macrocyclic peptide originally discovered by Ra Pharmaceuticals using their ExtremeDiversity platform, which screens large combinatorial libraries of macrocyclic peptides for high-affinity target binding. The macrocyclic architecture provides several advantages over linear peptides, including enhanced metabolic stability, improved target affinity, and reduced conformational entropy upon binding.

Design Principles#

Zilucoplan's molecular design incorporates several key structural features:

1. Macrocyclization: Head-to-side chain lactam bridge between the Lys1 and Asp6 residues constrains the peptide backbone, reducing conformational flexibility and enhancing binding affinity
2. Unnatural amino acids: Four of the 15 residues are non-natural (N-methyl aspartate, tert-butylglycine, 7-azatryptophan, cyclohexylglycine), improving metabolic stability and target selectivity
3. Lipid-PEG modification: A C16 lipid chain attached via a short monodisperse polyethylene glycol (PEG) linker promotes albumin binding in circulation, extending plasma half-life
4. Optimized binding surface: The macrocyclic scaffold presents a pre-organized binding interface complementary to the C5 surface

Amino Acid Composition#

Chemical Properties#

Pharmacokinetics#

Zilucoplan exhibits pharmacokinetic properties that support once-daily subcutaneous self-administration:

• Tmax: 3-6 hours after subcutaneous injection
• Terminal half-life: Approximately 172 hours (~7 days)
• Steady state: Trough concentrations reached by approximately 4 weeks of daily dosing
• Complement inhibition: ~97.5% inhibition achieved by end of the first week at 0.3 mg/kg daily
• Absorption: Rapid and predictable from subcutaneous depot
• Distribution: Albumin binding via lipid-PEG modification extends circulation time

Pharmacodynamics#

The pharmacodynamic profile of zilucoplan is characterized by:

• Rapid complement inhibition within days of initiating treatment
• Consistent daily trough concentrations maintaining therapeutic complement suppression
• Dose-dependent relationship between plasma levels and complement inhibition
• Reversible complement suppression upon treatment discontinuation

Structural Comparison with Other C5 Inhibitors#

The approximately 40-fold size difference between zilucoplan and antibody-based C5 inhibitors is the key enabler of subcutaneous self-administration, as the small molecular size allows efficient absorption from the subcutaneous depot.

Stability#

Zilucoplan is formulated as a ready-to-use solution in pre-filled syringes. Key stability characteristics:

• Refrigerated storage at 2-8 degrees C (long-term)
• Room temperature stability up to 30 degrees C for a single period of up to 3 months
• The macrocyclic structure and unnatural amino acids contribute to proteolytic stability
• The PEG-lipid modification further protects against renal elimination

Related Reading#

• Zilucoplan overview and research guide
• Peptides similar to zilucoplan
• Zilucoplan research evidence